{
    "clinical_study": {
        "@rank": "70330", 
        "arm_group": {
            "arm_group_label": "Fat Reduction", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety and feasibility of reducing human sebum production using the ZELTIQ\n      System."
        }, 
        "brief_title": "A Pilot Clinical Trial Investigating the Effect of Cutaneous Cooling on Sebum Production", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Body Fat Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Sphingolipidoses", 
                "Lipid Metabolism Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          1. Male subjects >18 years of age and <25 years of age.\n\n          2. Subject has an average sebum output on their upper back of at least 20, as measured\n             by the sebumeter\n\n          3. Subject has Fitzpatrick Skin Phototypes I-III (see Appendix A)\n\n          4. Willingness to participate in the study\n\n          5. Willingness to receive EXPERIMENTAL treatment\n\n          6. Informed consent agreement signed by the subject\n\n          7. Willingness to follow the treatment schedule and post treatment care requirements\n\n          8. Willingness to not use topical or systemic retinoids or antibiotics during the course\n             of the treatment\n\n        Exclusion criteria\n\n          1. Subject has a history of isotretinoin use\n\n          2. Subject has an infection or other dermatologic condition (aside from acne) in the\n             area to be treated\n\n          3. Subject has known cold sensitivity disorders including Raynaud's phenomena, cold\n             urticaria, cryoglobulinemia, and cold induced hemoglobinuria\n\n          4. Presence of suntan in the area to be treated\n\n          5. Subject is immunosuppressed\n\n          6. Subject is unable to comply with treatment, home care or follow-up visits\n\n          7. Subject has a history of vitiligo\n\n          8. Subject has a history of keloid formation\n\n          9. Subject is currently enrolled in a clinical study of any other unapproved\n             investigational drug or device.\n\n         10. Any other condition or laboratory value that would, in the professional opinion of\n             the investigator, potentially affect the subject's response or the integrity of the\n             data or would pose an unacceptable risk to the subject."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "25 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01686841", 
            "org_study_id": "ZA12-003"
        }, 
        "intervention": {
            "arm_group_label": "Fat Reduction", 
            "description": "Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.", 
            "intervention_name": "The Zeltiq System", 
            "intervention_type": "Device", 
            "other_name": [
                "Cryolipolysis", 
                "Lipolysis"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Lipolysis", 
            "Cryolipolysis", 
            "Fat Reduction"
        ], 
        "lastchanged_date": "March 26, 2013", 
        "location": {
            "contact": {
                "email": "hjalian@partners.org", 
                "last_name": "H. Ray Jalian, MD", 
                "phone": "617-643-6211"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": {
                "last_name": "R. Rox Anderson, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "PILOT STUDY OF NON-INVASIVE FAT LAYER REDUCTION IN THE FLANKS OF ASIAN PATIENTS WITH THE COOLCURVE+ APPLICATOR", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "\u2022 Reduction of sebum production as measured by the sebumeter at 2 weeks post-treatment. A 30% reduction of sebum production in any study cohort will be considered clinically meaningful.", 
                "measure": "Feasibility: Reduction of Sebum Production", 
                "safety_issue": "No", 
                "time_frame": "12 weeks post final treatment"
            }, 
            {
                "description": "Frequency of unanticipated adverse device effects (UADEs). Acceptance criteria: zero incidence of UADEs.", 
                "measure": "Safety: UADE", 
                "safety_issue": "No", 
                "time_frame": "12 weeks post final treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01686841"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022 Secondary safety endpoint: frequency of device- or procedure-related adverse events, and assessment of side effects.", 
                "measure": "Safety: AE's", 
                "safety_issue": "No", 
                "time_frame": "12 weeks post final treatment"
            }, 
            {
                "description": "\u2022 Reduction of sebum production as measured by the sebumeter at 72 hours, 1 week, and 4 weeks post-treatment.", 
                "measure": "Feasibility: Reduction of Sebum Production", 
                "safety_issue": "No", 
                "time_frame": "12 weeks post final treatment"
            }
        ], 
        "source": "Zeltiq Aesthetics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zeltiq Aesthetics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}